AbbVie to Acquire ImmunoGen for $10.1B
Shots:
- AbbVie announces the acquisition of ImmunoGen, including its Elahere antibody-drug conjugate (ADC) for platinum-resistant ovarian cancer in a $10.1B deal
- As per the deal, AbbVie will purchase all outstanding shares of ImmunoGen at a rate of $31.26 per share. Additionally, the agreement provides AbbVie access to Elahere (mirvetuximab soravtansine-gynx), which received FDA accelerated approval last year
- The deal, expected to close in mid-2024, & ImmunoGen's subsequent pipeline of ADCs will be made available to AbbVie
Ref: Finance Yahoo | Image: ImmunoGen
Related News:- ImmunoGen Collaborates with Takeda to Develop and Commercialize Elahere to Treat Platinum-Resistant Ovarian Cancer in Japan
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
